| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 2.5K Cr | 7.6% | 17.5% |
| Total Income | 2.6K Cr | 8.0% | 17.3% |
| Expenditure | 2.2K Cr | 8.4% | 19.7% |
| PBT | 358.80 Cr | 12.8% | 3.2% |
| Net Profit | 272.80 Cr | 0.6% | 2.3% |
| OPM | 21.48% | 0.50pp | 1.75pp |
| NPM | 10.66% | 0.79pp | 1.57pp |
| EPS | 3.53 | 0.3% | 2.3% |
Hospital margin expansion on track; watch diagnostics for pivot to double-digit growth
Fortis reports Q1 FY27 on August 6 with Street expecting ~₹2,350 Cr revenue and EBITDA margin progression toward its 25% hospital target by FY28. The hospital segment has driven the recent beat; the diagnostic business signals inflection—watch for confirmation.
What to expect
~₹2,350 Cr
On-plan YoY ~17%; Q4 FY26 delivered ₹2,365 Cr (+17.8%)
~23–24%
Progressing toward hospital 25% target (FY28); Q4 delivered 22.5%
High-teens growth
Prior Q1 +18.6%, occupancy 69%; watch for sequential ARPOB trend
Double-digit target
Prior Q1 +6.3% revenue; gross revenue +7.4%; management targets 10%+
A strong print: Revenue ₹2,350+ Cr with hospital occupancy holding 68–70% and ARPOB growth intact; diagnostics revenue growth clearly above prior-quarter 6.3% (confirmation of 10%+ trajectory); EBITDA margin at or above 23.5%, showing steady progress toward FY28 hospital margin target. A weak print: Revenue below ₹2,300 Cr (growth decelerating below 16%); occupancy slipping below 68%; diagnostics flat or low-single-digit; margin compression below 22.5%.
On track?
Yes, trajectory intact. FY26 delivered ₹9,128 Cr consolidated revenues (+17.3%) and ₹1,064 Cr PAT (+31.5%), confirming the 17%+ growth run-rate. Q4 FY26 accelerated: ₹2,365 Cr revenue (+17.8%) and margin at 22.5%, setting up Q1 FY27 as a continuation quarter. Management's hospital EBITDA margin target of 25% by FY28 implies 1.5–2% annual improvement; Q4 hit 22.5%, so Q1 at 23–24% keeps that cadence. The hospital business (85% of revenue) is the growth and margin engine. Diagnostics—at 23% EBITDA margin in Q1 FY26—is being asked to accelerate revenue growth from mid-single to double-digit; that inflection is a watch-item.
What the Street says
Since last quarter
1 · Agilus Diagnostics MD change (Jul 20)
New MD & CEO Vijender Singh appointed, 30+ years experience. Diagnostic growth inflection may hinge on this leadership shift—watch for commentary on strategy/capacity.
2 · Board meeting (Aug 6) + AGM (Aug 11)
Q1 results approval today; shareholder meeting Aug 11 will vote on ₹1 final dividend for FY26. Record date Jul 24; routine capital return, no surprise.
3 · Odisha expansion (Jul 3)
O&M agreement with Dion Group for 300-bed multi-specialty hospital in Cuttack. Entry into new state supports long-term 1,800-bed capacity plan; no material Q1 contribution expected.
4 · Tax relief (Jun 17)
Subsidiary tax demand (AY 2024–25) reduced from ₹92+ Cr to ₹61.48 Cr via rectification. Non-cash benefit; positive for FY27 effective tax rate, no Q1 impact.
5 · ESG improvement (Jul 17)
BRSR ESG rating rose to 68 (FY26) from 58 (FY24). Routine non-financial disclosure; no operational implication.
6 · MD re-appointment (Jul 8)
Dr. Ashutosh Raghuvanshi re-appointed for two-year term (effective Mar 19, 2027). Continuity signal; AGM to ratify Aug 11.
7 · FII outflow (Q4 data)
FII holding declined 1.87pp QoQ to 25.97% (Q4 FY26), DII +2.02pp. Modest portfolio rotation; no insider pledging flagged.
The setup
Fortis is a mid-cap hospital operator executing a clear margin-and-scale playbook: grow hospital revenue 16–18% YoY with steady 1.5–2% EBITDA margin improvement annually toward a 25% FY28 target, while accelerating diagnostics from a mid-single-digit base to double-digit. Q4 FY26 delivered: ₹2,365 Cr revenue and 22.5% margin, confirming the trajectory. Q1 FY27 will test whether the hospital segment holds momentum (Q1 historically softer than Q4) and whether diagnostics, with new MD in place, begins to inflect upward. Valuation at ₹940 sits 14.9% below ATH and below both 20- and 50-day SMAs, but still above the 200-day; analyst consensus of ₹1,075 (Strong Buy) prices in execution. Three things matter on result day: (1) Revenue staying above ₹2,300 Cr (17%+ growth); (2) EBITDA margin holding 23%+ (on track to 25% FY28); (3) Diagnostics revenue growth ticking above 8–10% (sign of the inflection).
Fortis reports Q1 FY27 on August 6. Expectations: ~₹2,350 Cr revenue (YoY ~17%), EBITDA margin ~23–24%, hospital segment growth 16–18%, diagnostics acceleration toward double-digit. Management guidance intact (25% hospital margin by FY28, 1.5–2% annual improvement). Street consensus Strong Buy at ₹1,075 12-month target. Recent filings routine; Agilus Diagnostics new MD a watch-item for diagnostic strategy. Watch for: (1) revenue run-rate confirmation; (2) margin progression; (3) diagnostics growth inflection; (4) occupancy and ARPOB trends in hospital segment.
17.5% Revenue Growth Can't Mask 2.3% Profit Growth — Margin Compression and Guidance Delays
Strong hospital revenue (+19%) and consolidated growth (+17.5%) mask the real story: net profit grew only 2.3% due to margin compression from oncology pricing cuts, new unit drag, and a ₹40 Cr quarterly ESOP charge starting next quarter. Management also overstated PAT growth and pushed margin recovery targets back a full year.
On the headline, Q1 looks like a beat: revenues grew 17.5%, hospital business delivered 19% growth well ahead of the prior 15%+ guidance, and bed count jumped 17%. But dig into profit, and the quarter tells a different story. Net profit grew just 2.3% — a 15-point wedge between revenue and earnings growth that exposes margin compression at the core of the business.
₹2,545 Cr
+17.5% YoY
₹2,187 Cr
+19% YoY (beat 15%+)
₹272.8 Cr
+2.3% YoY (vs +17.5% revenue)
21.5%
−60 bps vs prior year
Where the profit gap came from
Three headwinds compressed margins and killed profit growth: (1) Oncology pricing collapse. Government chemo drug reimbursement (ECHS/CGHS) cut by 30% on MRP, slowing oncology revenue from 23–24% growth to just 5%. That 18-point slowdown in a high-margin specialty is a structural headwind, not a one-quarter bump. Management expects stabilization at 10–12% but that's still half prior growth. (2) New hospital dilution. Manesar, Greater Noida, and recent acquisitions are ramping at 20% margins. This drag is quantified at −0.4% to consolidated margin now, with a +1% swing promised once these units stabilize (Manesar oncology fit-out November 2026, occupancy ramps through year-end). (3) ESOP charge starting Q2. ₹40 Cr per quarter (~14% of quarterly EBITDA, ~56–60 bps margin impact) will hit from August onwards. Management maintains its 25% margin guidance by FY28 by banking on ESOP-driven efficiency gains (doctor consumption control, occupancy leverage) and new unit ramp, but that offset is contingent, not proven.
Hospital revenue 19% YoY to ₹2,187 Cr
SupportedDelivered ₹2,187 Cr; math confirms 19% growth
Consolidated revenue 17.5% YoY to ₹2,545 Cr
SupportedDelivered ₹2,545 Cr; growth rate confirmed
PAT increased approximately 4% to ₹263 Cr
ContradictedDelivered ₹272.8 Cr; actual growth only 2.3%, not 4%
Hospital EBITDA margin 21.5% (60 bps compression from 22.1%)
SupportedDelivered OPM 21.5%; ex-acquisitions ~22%
25% EBITDA margin guidance by FY28 (post-ESOP offset)
OverstatedGuidance maintained; dependent on new unit ramp (+1%) and ESOP efficiency (~14% of EBITDA charge). Execution risk high.
What changed on this call
Three material shifts from prior guidance and expectation: (1) Margin guidance timeline extended. Prior FY26 call: 150–200 bps improvement to ~24% by FY27. This call: 25% target by FY28 (one year later). The delay is driven by oncology pricing headwind (permanent ~100–150 bps drag) and new unit ramp longer than expected. Margin recovery is now contingent on ESOP efficiency (unproven) and occupancy gains, not organic cost management. (2) Diagnostic growth tempered. Delivery: 10.2% vs implied industry 15%. New MD (Vijender Singh, 10 days in role) acknowledged slowness and committed to acceleration via B2C mix shift (53% now, target 55–58%) and NCR regional success replication. But timeline vague: 'next few quarters.' Meanwhile, industry grows 15% — Agilus is losing share. (3) Oncology specialty mix permanently impaired. Prior: 23–24% YoY growth, a flagship high-margin specialty. Q1 FY27: 5% growth. Management expects stabilization at 10–12%, not prior double-digit rates. This is a government-mandated margin drag, structural not cyclical.
Bull-bear ledger
Hospital revenue beat guidance (19% vs 15%+ expected); momentum strong
Bed expansion on track: 100 beds Q1, 400 planned FY27 (FMRI 200 imminent); 2,000-bed brownfield plan affirmed
14 of 69 hospitals >20% EBITDA (70% of revenue); high-margin cluster stable; scale leverage evident
Diagnostic EBITDA margin improved to 23.9% from 23%; B2C/specialty mix shift working
Consolidated PAT growth only 2.3% despite 17.5% revenue; massive margin compression
Oncology growth slowed 18 points (23% to 5%) due to government pricing; permanent headwind
Diagnostic growth 10.2% vs 15% industry; market share loss accelerating; new MD still unproven
ESOP charge ₹40 Cr/quarter (~14% of EBITDA) starting Q2; margin offset contingent on execution
Margin guidance pushed back 12 months (24% FY27 → 25% FY28); multiple moving parts, execution risk
Collection delays from government and TPA; provision for doubtful debt increased; cash flow risk
Risks ranked by holder concern
Government pricing intervention on specialty drugs (chemo 30% discount; oncology growth 23% → 5%)
HighRegulatory headwind is structural, not cyclical. Similar intervention could hit other government-reimbursed specialties (dialysis, orthopedics). Pricing power in govt segments permanently compromised. Margin drag ~100–150 bps. Similar risk to peers.
New hospital ramp-up execution (Manesar, Greater Noida, Gleneagles O&M currently <10–15% EBITDA)
HighMargin recovery to 25% by FY28 depends on these units reaching 20%+ EBITDA. Manesar oncology is November 2026 (3mo away); Gleneagles stabilization 2–4 qtrs out. Any delay pushes margin timeline further. Occupancy and talent acquisition critical; not fully controlled.
ESOP charge (₹40 Cr/qtr) and efficiency offset unproven
High₹40 Cr/qtr is ~56–60 bps margin headwind. Management maintaining 25% guidance assumes ESOP drives cost reduction and doctor productivity gains. If offset doesn't materialize, FY28 margin target misses by 50–100 bps. Contingent, not proven.
Diagnostic market share loss (10.2% growth vs 15% industry; new MD unproven at Agilus)
HighAgilus is losing ~5% market share annually. New MD (10 days tenure) is experienced but unproven at this org. B2C shift and NCR replication is the plan, but execution timeline vague ('next few quarters'). Competitors have better momentum; Agilus could become a drag on consolidated margins if trend persists.
Collection delays from government and TPA; receivables provision increasing
MediumProvision for doubtful debt increased Q1; exact amount not disclosed. Slows cash conversion and working capital. Impacts near-term liquidity. Being addressed but no firm timeline. Government reimbursement cycles slow; TPA bottlenecks persistent.
PAT growth severely lags revenue growth; profit quality declining
MediumRevenue +17.5% but PAT +2.3% is a red flag for earnings sustainability. Suggests margin compression is broad-based (oncology, new units, ESOP, collections) not isolated. If compression persists, profit growth could turn negative in Q2–Q3 before ESOP offset kicks in.
How the street is positioned
Price action: The stock popped 3.82% on day 1 post-result (delivery 84.6% — strong institutional buying), then faded to +1.65% by day 3 and −1.51% by day 5. The market initially bought the revenue beat, but sold the profit disappointment and margin delay. That fade-by-day-5 is the street's own verdict on the quarter: revenue is not enough to offset profit growth lag and guidance pushback. Valuation context: At ₹929, the stock is 12.99% below its all-time high, trading below its 20-day and 50-day moving averages (₹939 and ₹957 respectively) but above its 200-day (₹920). The 52-week range is ₹766.8–₹1,067.7; the stock has recovered 21.15% off the low but remains in correction from prior peaks. RSI at 45.9 is neutral (not oversold, not overbought). Ownership flows: FII ownership dropped 77 bps to 25.20% (from 25.97% prior quarter) — foreign institutions are trimming on profit concerns. DII ownership rose 88 bps to 32.23% (from 31.35%) — domestic institutions are accumulating on conviction that new units and ESOP will drive recovery. Promoter stake unchanged at 31.17%. The divergence (FII selling, DII buying) suggests uncertainty: foreign investors are taking defensive positioning, while domestic investors are betting on near-term execution recovery.
The debate
1 · Manesar oncology equipment installation (November 2026 target)
Q1 delivery: 187 beds at 60% occupancy, <10% EBITDA. Q2 call should confirm oncology capex and timeline. November completion would unlock comprehensive cancer center positioning and drive occupancy ramp. If delayed, margin recovery extends beyond FY28.
2 · Q2 PAT growth with ESOP charge in place
Q2 onwards, ESOP charge (₹40 Cr/qtr) will be fully booked. If PAT growth remains <5% despite ESOP starting, it signals cost control is not offsetting the charge. This will force management to lower FY28 margin guidance.
3 · Diagnostic acceleration pace under new MD
New MD committed to 12–13% growth rest of FY27 (vs Q1's 10.2%) and reaching industry-level 15% growth 'within next few quarters.' Q2 delivery will show if B2C mix shift and NCR replication are working. If growth stays <11%, new MD's effectiveness is in question.
4 · FMRI flagship occupancy after 200-bed expansion
FMRI is the company's highest-margin asset (~25% EBITDA). New 200 beds are expected to get occupancy certificate by month-end. Q2 call should detail ramp plan (target month-1 occupancy %, mix). Any occupancy shortfall below 40% in month-1 would be a red flag for new unit execution.
5 · Collection improvement from government and TPA
Provision for doubtful debt increased Q1 due to slow government/TPA collections. Q2 should show if management's 'working on' efforts are bearing fruit. Receivable aging and days sales outstanding (DSO) are critical — if DSO extends, cash flow deteriorates.
This is steady execution, not a step-change. Fortis has delivered on hospital bed expansion and maintained a strong core of high-margin facilities. But the margin compression from oncology pricing, new unit dilution, and ESOP charges is real, and profit growth has stalled. Management's path to 25% margins by FY28 is credible (quantified levers exist), but contingent on multiple executions aligning over the next 12 months. The near-term (Q2–Q3 FY27) is a prove-it phase: can ESOP drive efficiency, can new units ramp faster, and can Agilus accelerate under new leadership?
For holders: expect single-digit earnings growth through Q3, with upside unlocking only if Manesar oncology (November 2026) and Agilus acceleration (Q2–Q3) deliver. The rating is Hold — not a sell (hospital business is strong, bed plan is on track), but not a buy until near-term margin recovery is visible. The single number to track from here is PAT growth in Q2 FY27 — if it's <3% with full ESOP charge in place, it signals efficiency gains are not offsetting headwinds, and 25% margins by FY28 becomes a miss.
Strong revenue growth masked by margin compression and guidance delays
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met 15%+ hospital revenue growth. Missed on PAT growth (claimed 4%, delivered 2.3%). Margin guidance reaffirmed but ex-ESOP is softer. Diagnostic guidance maintained but low end of double-digit.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue growth (17.5%) and solid hospital scale (19% growth, 3,418 beds, 70% from 14 high-margin facilities) are offset by profit growth lag (2.3% vs revenue growth), near-term margin headwinds (ESOP ₹40 Cr/qtr, oncology pricing 5% growth vs prior 23%), and diagnostic underperformance (10% vs 15% industry). 25% margin target by FY28 is credible via new units and efficiency, but delayed vs prior guidance and dependent on execution. Hold pending near-term stabilization.
₹2545 Cr
Revenue · +17.5% YoY₹272.8 Cr
Reported PAT · +2.3% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Hospital revenue 19% YoY growth to ₹2,187 Cr
METDelivered ₹2,187 Cr implies Q1 FY26 base ~₹1,838 Cr; 19% confirmed by math
Consolidated revenue 17.5% YoY to ₹2,545 Cr
METDelivered ₹2,545 Cr; implies Q1 FY26 was ~₹2,169 Cr; matches guidance math
PAT increased approximately 4% to ₹263 Cr
MISSDelivered PAT ₹272.8 Cr, not ₹263 Cr. Actual YoY growth only 2.3%, not 4%
Hospital EBITDA margin 21.5% vs 22.1% prior year (60 bps compression)
METDelivered OPM 21.5% aligns with this. Management ex-acquisitions states margin 'similar to Q1 FY26 at 22%'
Diagnostic gross revenue 10.2% YoY growth vs industry 15%
METManagement acknowledges slower growth than peers; growth rate matches guidance
25% EBITDA margin guidance by FY28 (including ESOP cost offset)
OVERSTATEDQ1 at 21.5%, target is +350 bps over 4 qtrs. Dependent on new unit ramp (+1% swing) and ESOP efficiency gains (~14% of EBITDA charge). Achievable but not confirmed
Earnings quality
What changed since the last call
Margin guidance timeline extended
DowngradePrior FY26 call: 150-200 bps improvement to ~24% by FY27. Now: 25% by FY28, dependent on ESOP offset. Margin recovery delayed 4 quarters; contingent on new units ramping vs prior organic plan.
Diagnostic growth expectations tempered
DowngradePrior: double-digit growth (implied 12%+). Current delivery: 10.2%. Management guides 12-13% rest of year but industry is 15%. New MD joining but no aggressive acceleration committed; relying on B2C mix shift (53% now, targeting 55-58%).
Oncology specialty mix structurally impaired
DowngradePrior: oncology high-growth specialty (23-24% YoY). Q1 FY27: 5% due to government chemo pricing cut (30% discount ECHS/CGHS). Management expects stabilization at 10-12%, not prior growth rate. Permanent margin drag ~100-150 bps.
New unit expansion strategy affirmed
Upgrade2,000 bed brownfield plan on track. Q1 added 100 beds. FY27: 400 more planned (200 FMRI alone). Oncology fit-out (Manesar Nov, Faridabad/Amritsar starting) expected to unlock margin upside +1% over 12 months.
Inorganic strategy remains cluster-focused
NeutralNo major acquisitions announced. Management pursuing deals but won't disclose until concluded. Odisha O&M (300 beds) is learning play, no capex. Strategy unchanged: focus on existing clusters (Delhi NCR, Bangalore, Punjab, Mumbai, Kolkata).
The Q&A
Analysts pressed hard on near-term margin compression (Neha, Karan, Damayanti). Management held firm on 25% FY28 guidance, itemizing levers (new units +1%, ESOP efficiency, occupancy ramps, Manesar oncology). On diagnostics, Aman (IIFL) challenged slow 10% growth vs 15% industry; new MD (10 days in role) acknowledged stagnation and committed to acceleration, but timeline vague ('next few quarters'). Management tone was confident on strategy but candid on near-term headwinds.
ESOP strategy & criteria — Tausif, BNP Paribas
AnsweredBroad-based across all zones, not Delhi NCR only. 1.5 years of deliberation; strategic alignment of doctor interests with company performance, not reactionary. Doctors partner in efficiency (consumption control, profitability).
Margin guidance & ESOP offset — Tausif, BNP Paribas
PartialMargin guidance maintained. ESOP will contribute positively to operating performance through efficiency gains, offsetting cost. New units (FMRI, Manesar) and occupancy ramps provide additional levers.
25% margin guidance assumptions — Neha Manpuria, Bank of America
AnsweredPost-ESOP. Confidence high due to FMRI ready, Manesar ramping, multiple cost reduction initiatives. New units will contribute positively once stabilized.
Manesar & Noida margin recovery timeline — Neha Manpuria, Bank of America
AnsweredManesar: 187 beds operational (60% occupancy), oncology equipment Nov 2026; by year-end mid-teens margin expected. Noida: 8-10% month-on-month revenue growth, steady occupancy ramp; both facilities mid-teens to higher by year-end with talent acquisition.
Hospital margin levers to 25% — Karan Vora, Goldman Sachs
AnsweredNew units swing from -0.4% drag to +1% contribution. New doctors settling in 4 units. Legal costs from Delhi High Court hearing are transient (not baseline). Provision for doubtful debt being plugged (government/TPA collections lagging). Occupancy leverage in BG Road & Mulund (historically low). FMRI and Manesar oncology will drive incremental margin.
Bed expansion plan FY27 — Karan Vora, Goldman Sachs
Answered100 beds done Q1. 400 beds remaining Q2-Q4. Major: FMRI 200 beds (occupancy certificate expected this month). Others on track across Noida, Amritsar, Jalandhar.
ESOP charge quantification — Karan Vora, Goldman Sachs
AnsweredQ1 charge partial (from April 23). Q2-Q4 expected ~₹40 Cr/quarter if employee base stable. Year 2: ~₹30 Cr/quarter. Year 3: ~₹25 Cr/quarter.
Cluster strategy & Odisha entry — Damayanti Kerai, HSBC
AnsweredNo capital commitment in Odisha; O&M only (learning play). Strategy remains clusters: Bangalore, Delhi NCR, Punjab, Mumbai, Kolkata. Evaluating acquisitions in existing clusters. Odisha is option for future participation if O&M partner performs well.
Gleneagles O&M performance — Damayanti Kerai, HSBC
PartialCan't share specific numbers. General: significant improvement in operating margins across 5 facilities managed. New doctors, new teams. Margins moving positively but not yet Fortis standard; needs 2-4 quarters more stabilization.
Diagnostics slow growth vs industry — Aman Goyal, IIFL Capital
PartialNew MD (10 days tenure) will rework plans. Strategy: focus on sustainable profitable B2C-led growth (stickier, higher margin) vs pure volume chase. B2C ratio rising 53-55-58% trajectory. Region-wise seeing good NCR growth; will replicate elsewhere. Will reach industry levels 'within next few quarters' (no specific date).
Oncology specialty mix decline — Aman Goyal, IIFL Capital
AnsweredChemo business driven by government pricing (30% discount on MRP for ECHS/CGHS). Oncology growth slowed from 23-24% to 5%. Will stabilize at 10-12%. Focusing on radiation therapy & surgical oncology to maintain comprehensive care. Not operational failure; regulatory headwind.
Gleneagles management fee revenue — Aman Goyal, IIFL Capital
Answered3% of revenue per O&M agreement. Q1 FY27: ₹6 Cr.
Occupancy dynamics & high-margin facility growth — Abdulkader Puranwala, ICICI Securities
AnsweredBlended 70% occupancy reflects new unit dilution (renovations in Bangalore, new acquisitions). Core 14 facilities at strong occupancy. Levers: Manesar, Yeshwanthpur, Greater Noida ramp-ups. BG Road (historically low) is major opportunity. Expected 2-3% occupancy point improvement going forward via talent acquisition and marketing.
FMRI margin expectations post-bed addition — Abdulkader Puranwala, ICICI Securities
AnsweredFMRI at ~25% margin now. New beds will maintain and possibly improve margin. Initially some cost to add talent, but on larger base will preserve EBITDA %; upside possible as facility scales.
Capex guidance & M&A pipeline — Saion Mukherjee, Nomura
PartialGrowth phase: ~50% of EBITDA to brownfield expansion (2,000 bed plan). Also investing in proton, robotic surgery, advanced therapies. M&A: pursuing some deals but can't disclose until concluded. Deals focused on clusters.
ESOP breadth & attrition — Saion Mukherjee, Nomura
Answered55-60% of doctors and senior admin staff. Not only doctors. Proportion may vary by need. Attrition: Micro-market issue (Noida saw flutter when new hospitals opened). Supply of clinical talent improving significantly. Younger generation trained post medical college expansion 15y ago; won't be big problem going forward.
Proton therapy capex & timeline — Deepthi Rajulapati, Axis AMC
AnsweredUnder finalization. Capex ~₹252 Cr.
O&M call options — Deepthi Rajulapati, Axis AMC
AnsweredNo call options in 2-3 current O&M hospitals. Gleneagles discussions with IHH ongoing on path forward.
Diagnostic growth guidance rest of FY27 — Nilay Parekh, Perpetuity Ventures
AnsweredDiagnostic revenue: 12-13% for rest of FY27. EBITDA margin: 24-25% range for remaining time. Preventive portfolio trending up (14% now vs 12%), specialized up (35% vs 34%). Momentum to continue.
Guidance
Hospital: 15%+ growth (prior FY26 call); delivered 19% in Q1 FY27
HighBed expansion (100 Q1, 400 FY27 planned) and ARPOB gains (+2.6% Y1) drive revenue. FY27 guidance not formally re-guided but trajectory clear from Q1 beat
Diagnostic: double-digit growth maintained; 12-13% for rest of FY27
MediumQ1 delivered 10.2% vs 15% industry. New MD (Vijender Singh, 10 days in) guiding acceleration via B2C mix shift (53→55-58% target) and NCR regional replication. Timeline vague; '≈next few quarters' to match industry levels
Hospital EBITDA 25% by FY28 (maintained from prior FY26 call)
MediumPrior: 150-200 bps improvement to ~24% by FY27. Current: delayed to 25% by FY28. Dependent on new units ramp (+1% swing), ESOP efficiency offset (~₹40 Cr/qtr charge), occupancy improvement (2-3ppts), Manesar oncology Nov 2026. Multiple moving parts; execution risk.
Diagnostic EBITDA 24-25% for rest of FY27
HighQ1 delivered 23.9%; within guidance range. Portfolio mix shift (preventive +2%, specialized +1%) and B2C expansion support margin. Confidence high given immediate execution visible
FY27: ~50% of EBITDA for brownfield (2,000 bed program)
HighFMRI 200 beds imminent. Manesar/Greater Noida/Yeshwanthpur ramping. Faridabad/Amritsar oncology starting. Plus: Proton (₹252 Cr), robotic surgery, advanced therapies investment
Risks the call surfaced
Government pricing regulation
HighChemo drug pricing cut (30% discount on MRP for ECHS/CGHS) slowed oncology from 23-24% to 5% growth. Similar intervention could affect other specialties. Pricing power compromised in government segments.
Collection delays from government & TPA
MediumProvision for doubtful debt increased Q1 due to collection delays from government payor and TPA (Third Party Administrators). Impact on cash flow and working capital not quantified. Being worked on but no firm timeline to resolution.
New hospital margin ramp-up execution
HighManesar, Greater Noida, Gleneagles, and acquisition facilities currently below 10-15% EBITDA margin. Timeline to reach 20%+ EBITDA uncertain. Manesar depends on Nov 2026 oncology equipment fit-out. Occupancy growth and clinical talent acquisition critical. Delay would push margin recovery timeline beyond FY28.
Diagnostic growth slowdown vs industry
MediumAgilus growing 10.2% vs 15% industry growth. New MD (Vijender Singh) just joined (10 days); track record at Agilus unproven. Promises acceleration but vague timeline ('next few quarters'). Brand stabilization and rebranding completed but competitive position weakening. Risk: continued market share loss if acceleration doesn't materialize.
ESOP charge impact and efficiency unproven
Medium₹40 Cr per quarter ESOP charge (~14% of quarterly EBITDA ≈ ~56-60 bps margin impact) starting Q2 FY27. Management maintaining 25% margin guidance assuming ESOP drives efficiency gains and cost reduction ('better profitability profile'). Offset unproven; if efficiency gains don't materialize, margin guidance would miss.
Management
Score 7/10. Clear and operational. MD and CFO aligned on strategy and numbers. Direct answers to margin levers, capex, and M&A priorities. Transparent on new unit challenges (Manesar, Noida ramp timelines). Some hedging on M&A details (confidentiality of active deals) and diagnostic acceleration specifics (new MD still learning role). Mixed. Hospital revenue beat guidance (19% vs 15% prior). Diagnostic growth missed implicit guidance (10% vs 15% industry; double-digit guidance partially met). Margin guidance delayed (was 24% by FY27, now 25% by FY28 due to new unit drag and ESOP). Bed expansion on track (100 Q1, 400 planned FY27). New tech (proton, robots) investment proceeding.
1 · Nov 2026
Manesar radiation oncology equipment commissioned; transforms facility to comprehensive cancer center
2 · Q2 FY27 (Aug-Sep 2026)
FMRI flagship hospital 200 beds occupancy certificate expected; adds high-margin capacity
3 · Q2-Q3 FY27
Faridabad & Amritsar oncology brownfield expansion work starts; new revenue specialty
Hold pending near-term stabilization.